Literature DB >> 3784844

Clinical toxicology in the neonatal intensive care unit.

W Banner.   

Abstract

The role of the clinical toxicologist in the neonatal nursery may be an extremely important one in the evaluation of epidemic-like toxic reactions occurring from: (a) the inappropriate use of medications; (b) the accidental contamination of parenterals; and (c) the introduction of relatively new products into the nursery environment. The newborn with high respiratory demands, thin epidermis with a large surface area to body mass ratio, and nutritional support being derived completely from parenteral sources provides a great number of routes of entry for the introduction of toxins. In approaching these problems, the clinician needs a structured approach in considering the impact of the route of administration, the contents of the product and the ability of the newborn to eliminate the toxin in question. In addition, some knowledge of the specialised structures and diseases of the newborn is required to adequately analyse the impact of a potential toxin on newborn disease processes. What we normally consider as adverse drug reactions are extremely rare in the neonate. Hypersensitivity phenomenon and the classic non-dose-related side effects described in adults are rare occurrences. This makes it a challenge for the clinical toxicologist to analyse and attempt to identify a toxic substance in the nursery. Having identified a toxin in the newborn, treatment may be complicated by the inability to use many of the standard forms of therapy, e.g. activated charcoal, diuresis, and extracorporeal removal. The lack of practicality of these procedures increases the necessity for good supportive care. Exchange transfusion, rarely considered in older children and adults, may offer the only viable option for rapid removal of a drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3784844     DOI: 10.1007/bf03259839

Source DB:  PubMed          Journal:  Med Toxicol        ISSN: 0112-5966


  39 in total

1.  Unsuspected hyperosmolality of oral solutions contributing to necrotizing enterocolitis in very-low-birth-weight infants.

Authors:  D M Willis; J Chabot; I C Radde; G W Chance
Journal:  Pediatrics       Date:  1977-10       Impact factor: 7.124

2.  Pharmacokinetic aspects of theophylline in premature newborns.

Authors:  J V Aranda; D S Sitar; W D Parsons; P M Loughnan; A H Neims
Journal:  N Engl J Med       Date:  1976-08-19       Impact factor: 91.245

3.  Medication errors with inhalant epinephrine mimicking an epidemic of neonatal sepsis.

Authors:  S L Solomon; E M Wallace; E L Ford-Jones; W M Baker; W J Martone; I J Kopin; A D Critz; J R Allen
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

4.  Local and systemic reactions to the parenteral administration of vitamin E.

Authors:  D L Phelps
Journal:  Dev Pharmacol Ther       Date:  1981

5.  Caffeine toxicity in a neonate .

Authors:  P B Kulkarni; R D Dorand
Journal:  Pediatrics       Date:  1979-08       Impact factor: 7.124

6.  Pharmacokinetic considerations in exchange transfusion in neonates.

Authors:  G J Yakatan; R B Smith; R D Leff; J L Kay
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

7.  Evaluation of adverse renal reactions to prolonged indomethacin therapy in preterm infants with persistent ductus arteriosus.

Authors:  H W Seyberth; W Rascher; L Wille; E Hackenthal; H E Ulmer
Journal:  Pediatr Pharmacol (New York)       Date:  1983

8.  Acute caffeine overdose in the neonate.

Authors:  W Banner; P A Czajka
Journal:  Am J Dis Child       Date:  1980-05

9.  Evidence of aluminum loading in infants receiving intravenous therapy.

Authors:  A B Sedman; G L Klein; R J Merritt; N L Miller; K O Weber; W L Gill; H Anand; A C Alfrey
Journal:  N Engl J Med       Date:  1985-05-23       Impact factor: 91.245

10.  Vitamin E and retrolental fibroplasia. Improved visual outcome with early vitamin E.

Authors:  N N Finer; R F Schindler; K L Peters; G D Grant
Journal:  Ophthalmology       Date:  1983-05       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.